Pharmacoeconomic review report : Guselkumab (Tremfya) (Janssen Inc.)

Pharmacoeconomic review report Guselkumab (Tremfya) (Janssen Inc.)

Guselkumab (Tremfya) is a fully human immunoglobulin G1 lambda (IgG1a) monoclonal antibody that binds selectively to the interleukin 23 (IL-23) protein with high specificity and affinity. Levels of IL-23 are elevated in the skin of patients with plaque psoriasis and guselkumab exerts its clinical ef...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : CADTH 2018.
Materias:
Monoclonal antibodies > Therapeutic use.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820269606719
Tabla de Contenidos:
  • Abbreviations
  • Executive Summary
  • Background
  • Summary of Identified Limitations and Key Results
  • Conclusions
  • Information on the Pharmacoeconomic Submission
  • Summary of the Manufacturer's Pharmacoeconomic Submission
  • Manufacturer's Base Case
  • Summary of Manufacturer's Scenario Analyses
  • Limitations of Manufacturer's Submission
  • CADTH Common Drug Review Reanalyses
  • Patient Input
  • Conclusions
  • Appendix 1. Cost Comparison
  • Appendix 2. Additional Information
  • Appendix 3. Health Technology Assessment Reviews of Drug
  • Appendix 4. Reviewer Worksheets
  • References.

Ejemplares similares